BIIB Biogen

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Global biopharmaceutical company developing and commercializing therapies primarily for neurology, specialized immunology, and rare diseases
• • New or emphasized segment: Expanded collaboration with Genentech on multiple anti-CD20 therapies including recently approved GAZYVA for lupus nephritis in Oct 2025

Risk Factors

• • Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty
• • Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025

Management Discussion & Analysis

• • No specific revenue or YoY change figures disclosed in provided text
• • No profitability or margin figures mentioned

Risk Factors

• • New risk: Generic TECFIDERA competition started in North America, Brazil, Europe triggering revenue decline and ongoing patent litigation in Europe through 2028
• • Most updated risk: Impact of Inflation Reduction Act (IRA) Medicare Part D redesign expected to reduce 2025 revenue by $50-100M, mainly on SKYCLARYS and MS portfolio

Management Discussion & Analysis

• • Revenue $2.535B for Q3 2025, up $68.9M (2.8%) YoY from $2.466B in Q3 2024
• • Operating margin approx. 21.7% in Q3 2025 ($557.3M income before tax on $2.535B revenue) vs 18.3% in Q3 2024 ($451.0M on $2.466B)

What are the latest BIIB SEC filings in 2026?

Biogen (BIIB) has filed a 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BIIB file its most recent 10-K annual report?

Biogen (BIIB) filed its most recent 10-K annual report on February 6, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BIIB 10-Q quarterly reports?

Biogen (BIIB)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every BIIB 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BIIB filed recently?

Biogen (BIIB)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BIIB insider trading activity (Form 4)?

SignalX aggregates every BIIB Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BIIB file with the SEC?

Biogen (BIIB) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BIIB filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Biogen (BIIB).

What is BIIB's SEC CIK number?

Biogen (BIIB)'s SEC CIK (Central Index Key) number is 875045. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 875045 to look up all BIIB filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BIIB return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Biogen (BIIB) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.